NL-OMON44109已完成4 期
Investigation of the AcrySof® IQ PanOptix* Presbyopia Correcting IOL Model TFNT00 - Investigation of the AcrySof® IQ PanOptix* IOL Model TFNT00
Alcon Laboratories0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Adults, 22 years of age or older at the time of surgery, of either gender or any race, diagnosed with bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision;;2. Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures;;3. Calculated lens power within the available range;;4. Preoperative BCDVA worse than 0.20 logMAR (ie, 0.22 logMAR or worse) in both eyes;;5. Potential postoperative BCDVA of 0.20 logMAR or better in both eyes based on Investigator expert medical opinion. (NOTE: Subjects with any pathology that could reduce visual potential should not be enrolled in this trial);;6. Preoperative regular corneal astigmatism of < 1.00 D, in both eyes;;7. Clear intraocular media other than cataract in both eyes.
排除标准
- •Prior operation;1. Clinically significant corneal abnormalities including corneal dystrophy (eg, epithelial,stromal, or endothelial dystrophy), inflammation or edema per the Investigator*s expert medical opinion.
- •Note: conditions including, but not limited to: keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or keratectasia should be excluded;;2. Previous corneal transplant;;3. Ocular trauma, previous refractive surgery or refractive surgery procedures throughout the entire duration of the subjects* participation in the clinical study (including, but not limited to LASIK, astigmatic keratotomy and limbal relaxing incisions);;4. History of or current retinal conditions or predisposition to retinal conditions, previous history of, or a predisposition to, retinal detachment or presence of diabetic retinopathy that the Investigator judges could confound outcomes (NOTE: Including but not limited to background diabetic retinopathy, diabetic macular edema or proliferative diabetic retinopathy, macular degeneration);;5. Ambylopia;;6. Rubella, congenital, traumatic, or complicated cataracts;;7. Extremely shallow anterior chamber (* 2.5 mm), not due to swollen cataract;;8. Any current anterior or posterior segment inflammation of any etiology, and /or history of any disease producing an intraocular inflammatory reaction;;9. Iris neovascularization;;10. Glaucoma (uncontrolled or controlled with medication) or ocular hypertension;;11. Optic nerve atrophy;;12. Subjects with diagnosed degenerative eye disorders;;13. Known color vision deficiencies;;14. Pregnancy or lactation;;15. Any subject currently participating in another investigational drug or device study that may confound the results of this investigation;;16. Subjects who may reasonably be expected to require an ocular surgical treatment at any time during the study (other than YAG capsulotomy);;17. Situations where the need for a large capsulotomy can be anticipated (eg, diabetics, retinal detachment in the fellow eye, peripheral retinal pathology, etc.);;18. Subjects who are expected to require retinal laser treatment.;During Surgery;1. Any other additional procedures during the phacoemulsification and IOL implant due to intraoperative complications that require further intervention (including but not limited to posterior capture rupture, vitreous loss, zonular dehiscence that may make the IOL implant less stable, etc.);;2. Zonular or Capsule rupture;;3. Excessive iris mobility;;4. Mechanical or surgical manipulation required to enlarge the pupil prior to or at IOL implantation (pupil size must be at least 4.5 mm or larger just prior to implantation);;5. Significant anterior chamber bleeding;;6. Uncontrolled intraocular pressure;;7. Unrecognized (pre-existing but discovered during surgery ocular conditions or complications in which the IOL stability could be compromised, including zonular weakness;;8. Any incision site other than temporal;;9. Bag-sulcus, sulcus-sulcus or unknown placement of the haptics;;10. Capsulorhexis tears or any areas of *can-opener* capsulotomy.
研究者
相似试验
已完成
不适用
Assessment of an intraocular lens to provide independence from optical aids at all distances following cataract surgery in patients with astigmatism.CataractACTRN12619001109190Alcon Laboratories12
已完成
不适用
Clinical Investigation of AcrySof® IQ PanOptix™ IOL Model TFNT00CataractNCT03280108Alcon Research250
已完成
不适用
Clinical Investigation of the AcrySof® IQ PanOptix™ IOLCataractNCT03090256Alcon Research76
已完成
不适用
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00CataractNCT02529488Alcon Research167
已完成
不适用
Post-Market Clinical Study of the PanOptix Intraocular Lens (IOL) in a Chinese PopulationPresbyopiaAphakiaNCT04755231Alcon Research181